Yan-Qing Song

Dr. Yan-Qing Song


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2019 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
JZJinghui Zhai
Jinghui Zhai
LTLina Tao
Lina Tao
SZSixi Zhang
Sixi Zhang
HGHuan Gao
Huan Gao
YZYueming Zhang
Yueming Zhang
XQXiaoyu Qu
Xiaoyu Qu

1 February 2020 in Toxicology
Verified
Journal Article
Closed access
XQXiaoyu Qu
Xiaoyu Qu
HGHuan Gao
Huan Gao
JSJingmeng Sun
Jingmeng Sun
LTLina Tao
Lina Tao
YZYueming Zhang
Yueming Zhang
ZLZhiyuan Li
Zhiyuan Li

1 July 2020 in Toxicology
Verified
Journal Article
Closed access
HGHuan Gao
Huan Gao
XWXiangfeng Wang
Xiangfeng Wang
XQXiaoyu Qu
Xiaoyu Qu
JZJinghui Zhai
Jinghui Zhai
LTLina Tao
Lina Tao
WZWenrui Zhang
Wenrui Zhang

1 August 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
YZYueming Zhang
Yueming Zhang
XQXiaoyu Qu
Xiaoyu Qu
HGHuan Gao
Huan Gao
JZJinghui Zhai
Jinghui Zhai
LTLina Tao
Lina Tao
JZJie Zhang
Jie Zhang

10 January 2019 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
LTLina Tao
Lina Tao
XQXiaoyu Qu
Xiaoyu Qu
YZYue Zhang
Yue Zhang
YSYan-Qing Song
Yan-Qing Song
SZSi-Xi Zhang
Si-Xi Zhang
Background. Prophylactic therapy with silymarin to prevent the development of antituberculosis drug-induced liver injury (anti-TB DILI) has been under debate. We aimed to evaluate the effect of silymarin in the prevention of anti-TB DILI. Methods. We searched MEDLINE, PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to 30th November 2018. Randomized controlled trials (RCTs) that compared silymarin and placebo to prevent anti-TB DILI were included. All statistical analyses were conducted using STATA 12.0 software. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CIs) were used to evaluate the effect of silymarin. The quality of included studies was assessed according to Cochrane handbook. Funnel plots and Egger’s tests were carried out to evaluate publication bias. Sensitivity analysis was conducted to assess the influence of each study. Results. A total of 1198 patients from five RCTs (585 with silymarin and 613 with placebo groups) were included. Overall, silymarin significantly reduced the occurrence of anti-TB DILI at week 4 [RR: 0.33, 95% CI (0.15, 0.75)]. In addition, silymarin exerted protective effect on liver function in patients undergoing anti-TB drugs [SMD = − 0.15, 95% CI (−0.24, −0.07), P < 0.001 (ALT); SMD =−0.14, 95% CI (−0.23, −0.06), P = 0.001(AST); SMD =−0.12, 95% CI (−0.20, −0.03), P = 0.008 (ALP)]. Silymarin led to similar AEs in placebo groups [OR: 1.09, 95% CI (0.86, 1.39), P = 0.47]. Conclusion. Prophylactic therapy of silymarin is contributed to a noticeably reduced risk of development of anti-TB DILI four weeks after the initiation. In addition, silymarin significantly improved the liver function in patients who are receiving anti-TB drugs.

1 May 2020 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
XQXiaoyu Qu
Xiaoyu Qu
HGHuan Gao
Huan Gao
JZJinghui Zhai
Jinghui Zhai
JSJingmeng Sun
Jingmeng Sun
LTLina Tao
Lina Tao
THTingting Hu
Tingting Hu